Results of the Seventh Scientific Workshop of ECCO: Precision Medicine in IBD-Disease Outcome and Response to Therapy

Bram Verstockt; Nurulamin M Noor; Urko M Marigorta; Polychronis Pavlidis; Parakkal Deepak; Ryan C Ungaro; Scientific Workshop Steering Committee

doi:10.1093/ecco-jcc/jjab050

Results of the Seventh Scientific Workshop of ECCO: Precision Medicine in IBD-Disease Outcome and Response to Therapy

J Crohns Colitis. 2021 Sep 25;15(9):1431-1442. doi: 10.1093/ecco-jcc/jjab050.

Authors

Bram Verstockt^{1

2}, Nurulamin M Noor^{3

4}, Urko M Marigorta^{5

6}, Polychronis Pavlidis^{7

8}, Parakkal Deepak⁹, Ryan C Ungaro¹⁰; Scientific Workshop Steering Committee

Collaborators

Scientific Workshop Steering Committee:
Claudio Fiocchi, Joana Torres, Michael Scharl

Affiliations

¹ University Hospitals Leuven Department of Gastroenterology and Hepatology, KU Leuven, Leuven, Belgium.
² KU Leuven Department of Chronic Diseases and Metabolism, Translational Research Center for Gastrointestinal Disorders [TARGID], Leuven, Belgium.
³ Department of Gastroenterology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Trust, Cambridge, UK.
⁴ Medical Research Council Clinical Trials Unit, University College London, London, UK.
⁵ Integrative Genomics Lab, Center for Cooperative Research in Biosciences [CIC bioGUNE], Basque Research and Technology Alliance [BRTA], Derio, Spain.
⁶ IKERBASQUE, Basque Foundation for Science, Bilbao, Spain.
⁷ Department of Gastroenterology, Guy's and St Thomas' NHS Foundation Trust, London, UK.
⁸ School of Immunology and Microbial Sciences, King's College London, London, UK.
⁹ Inflammatory Bowel Diseases Center, Washington University in Saint Louis School of Medicine, St Louis, MO, USA.
¹⁰ Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Abstract

Inflammatory bowel diseases [IBD] are a heterogeneous spectrum with two extreme phenotypes, Crohn's disease [CD] and ulcerative colitis [UC], which both represent numerous phenotypical variations. Hence, we should no longer approach all IBD patients similarly, but rather aim to rethink clinical classifications and modify treatment algorithms to usher in a new era of precision medicine in IBD. This scientific ECCO workshop aims to provide a state-of-the-art overview on prognostic and predictive markers, shed light on key questions in biomarker development, propose best practices in IBD biomarker development [including trial design], and discuss the potential for multi-omic data integration to help drive further advances to make precision medicine a reality in IBD.

Keywords: Precision medicine; disease outcome; disease prognosis; inflammatory bowel diseases; personalised medicine; response to therapy.

Publication types

Review

MeSH terms

Algorithms
Biomarkers / metabolism
Humans
Inflammatory Bowel Diseases / diagnosis*
Inflammatory Bowel Diseases / etiology
Inflammatory Bowel Diseases / therapy*
Outcome Assessment, Health Care
Precision Medicine*
Prognosis

Substances

Biomarkers

Grants and funding

K23 DK111995/DK/NIDDK NIH HHS/United States